Molecular Data Inc.
Molecular Data Inc., through its subsidiaries, operates in the chemical e-commerce business in the People's Republic of China. The company operates technology-driven platform that connects participants along the chemical value chain through its integrated solutions. It delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and software-as-a-service suites for par… Read more
Molecular Data Inc. (MKDTY) - Net Assets
Latest net assets as of September 2021: $64.64 Million USD
Based on the latest financial reports, Molecular Data Inc. (MKDTY) has net assets worth $64.64 Million USD as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($746.09 Million) and total liabilities ($681.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $64.64 Million |
| % of Total Assets | 8.66% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Molecular Data Inc. - Net Assets Trend (2017–2020)
This chart illustrates how Molecular Data Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Molecular Data Inc. (2017–2020)
The table below shows the annual net assets of Molecular Data Inc. from 2017 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | $-27.88 Million | +54.76% |
| 2019-12-31 | $-61.62 Million | 0.00% |
| 2018-12-31 | $-61.62 Million | -1144.31% |
| 2017-12-31 | $5.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Molecular Data Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 77620400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $114.00K | % |
| Other Comprehensive Income | $-21.19 Million | % |
| Other Components | $1.08 Billion | % |
| Total Equity | $-27.93 Million | 100.00% |
Molecular Data Inc. Competitors by Market Cap
The table below lists competitors of Molecular Data Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Emperador Inc.
PSE:EMI
|
$2.44K |
|
Americann Inc
PINK:ACAN
|
$2.44K |
|
Missfresh Limited
PINK:MFLTY
|
$2.44K |
|
WING TAI PROP (USH.SG)
STU:USH
|
$2.45K |
|
Blue-Ex
KAR:GEMBLUEX
|
$2.44K |
|
HUD1 Investment and Construction JSC
VN:HU1
|
$2.43K |
|
Egyptians Real Estate Fund Certificates
EGX:EGREF
|
$2.43K |
|
WSS
VN:WSS
|
$2.43K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Molecular Data Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from -61,625,000 to -27,928,000, a change of 33,697,000.
- Net loss of 328,038,000 reduced equity.
- New share issuances of 419,955,000 increased equity.
- Other comprehensive income decreased equity by 20,876,000.
- Other factors decreased equity by 37,344,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-328.04 Million | -1174.58% |
| Share Issuances | $419.95 Million | +1503.71% |
| Other Comprehensive Income | $-20.88 Million | -74.75% |
| Other Changes | $-37.34 Million | -133.72% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Molecular Data Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.77 | $0.00 | x |
| 2018-12-31 | $-8.04 | $0.00 | x |
| 2019-12-31 | $-8.93 | $0.00 | x |
| 2020-12-31 | $-3.61 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Molecular Data Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.32%
- • Asset Turnover: 11.09x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-456.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -1826.93% | -2.57% | 11.02x | 64.59x | $-108.40 Million |
| 2018 | 0.00% | -2.81% | 24.36x | 0.00x | $-248.48 Million |
| 2019 | 0.00% | -1.46% | 35.65x | 0.00x | $-187.39 Million |
| 2020 | 0.00% | -4.32% | 11.09x | 0.00x | $-325.25 Million |
Industry Comparison
This section compares Molecular Data Inc.'s net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $4,077,754,889
- Average return on equity (ROE) among peers: -50.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Molecular Data Inc. (MKDTY) | $64.64 Million | -1826.93% | 10.54x | $2.44K |
| Synalloy Corporation (ACNT) | $102.48 Million | 12.78% | 1.23x | $94.68 Million |
| Advance ZincTek Limited (ADVNF) | $35.28 Million | 4.71% | 0.11x | $5.02 Million |
| AdvanSix Inc (ASIX) | $738.18 Million | 23.29% | 1.03x | $435.20 Million |
| ASP Isotopes Inc. Common Stock (ASPI) | $51.17 Million | -63.19% | 0.84x | $409.15 Million |
| Braskem SA Class A (BAK) | $2.54 Billion | -64.23% | 1.22x | $936.09 Million |
| Bachem Holding AG (BCHMF) | $447.82 Million | 12.10% | 0.45x | $1.98 Billion |
| BASF SE NA O.N. (BFFAF) | $34.76 Billion | 17.49% | 1.27x | $47.09 Billion |
| BioLargo Inc (BLGO) | $1.14 Million | -442.98% | 0.67x | $51.87 Million |
| Black Swan Graphene Inc. (BSWGF) | $14.00 Million | -13.86% | 0.01x | $10.07 Million |
| Celanese Corporation (CE) | $2.10 Billion | 8.02% | 2.06x | $6.44 Billion |